This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Aug;16(8):1011.

doi: 10.1007/s00198-005-1882-8.

On some osteoporosis analyses

PMID: 15864411
DOI: 10.1007/s00198-005-1882-8

Comment

On some osteoporosis analyses

A D Tsakok. Osteoporos Int. 2005 Aug.

. 2005 Aug;16(8):1011.

doi: 10.1007/s00198-005-1882-8.

Author

PMID: 15864411
DOI: 10.1007/s00198-005-1882-8

No abstract available

PubMed Disclaimer

Comment on

Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies.
Reginster JY, Meunier PJ. Reginster JY, et al. Osteoporos Int. 2003;14 Suppl 3:S56-65. doi: 10.1007/s00198-002-1349-0. Epub 2003 Mar 12. Osteoporos Int. 2003. PMID: 12730797 Clinical Trial.
The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E. Bhattoa HP, et al. Osteoporos Int. 2004 May;15(5):396-404. doi: 10.1007/s00198-003-1553-6. Epub 2003 Dec 16. Osteoporos Int. 2004. PMID: 14676992 Clinical Trial.

Similar articles

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY. Bruyere O, et al. J Clin Endocrinol Metab. 2007 Aug;92(8):3076-81. doi: 10.1210/jc.2006-2758. Epub 2007 Jun 12. J Clin Endocrinol Metab. 2007. PMID: 17566094 Clinical Trial.
By the way, doctor. What can you tell me about the mineral strontium, which is advertised for treating osteoporosis?
Robb-Nicholson C. Robb-Nicholson C. Harv Womens Health Watch. 2007 Aug;14(12):7. Harv Womens Health Watch. 2007. PMID: 17722357 No abstract available.
[New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
Shiraki M. Shiraki M. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:447-53. Nihon Rinsho. 2007. PMID: 18161147 Review. Japanese. No abstract available.
Strontium strengthens some bones.
[No authors listed] [No authors listed] Health News. 2004 Mar;10(3):7. Health News. 2004. PMID: 15017937 No abstract available.
[Osteoporosis: from cost-effect characteristics to clinical efficacy and safety of strontium ranelate (bivalos)].
Dydykina IS, Tsurko VV. Dydykina IS, et al. Ter Arkh. 2008;80(5):85-91. Ter Arkh. 2008. PMID: 18590124 Review. Russian. No abstract available.

See all similar articles

References

1. Ophthalmic Epidemiol. 2002 Dec;9(5):347-8 - PubMed
1. Osteoporos Int. 2003;14 Suppl 3:S56-65 - PubMed
1. Osteoporos Int. 2004 May;15(5):396-404 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Medical
- MedlinePlus Health Information